Compare EPSN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | ACET |
|---|---|---|
| Founded | 2005 | 1947 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 71.3M |
| IPO Year | N/A | N/A |
| Metric | EPSN | ACET |
|---|---|---|
| Price | $4.59 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 115.2K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | ★ 11.33 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,709,605.00 | N/A |
| Revenue This Year | $41.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.73 | ★ N/A |
| Revenue Growth | ★ 46.76 | N/A |
| 52 Week Low | $4.36 | $0.45 |
| 52 Week High | $8.50 | $1.11 |
| Indicator | EPSN | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 36.30 |
| Support Level | $4.76 | $0.46 |
| Resistance Level | $5.09 | $0.59 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 1.82 | 21.32 |
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.